1 January 2023 in Endocrinology: News, Opinions, Training
Ремиссия сахарного диабета 2 типа у пациентов с ожирением после бариатрических операций
26 June 2020 in Nephrology (Saint-Petersburg)
The relevance of the study of glycemic variability in patients with diabetes mellitus and diabetic nephropathy is due to disability of the able-bodied population and high mortality against the background of the almost irreversible progression of diabetic nephropathy. The article highlights modern ideas about the influence of various factors on the occurrence of diabetic nephropathy and its course. The article is devoted to a review of current recommendations on diabetes mellitus and diabetic nephropathy; the etiopathogenesis of diabetic nephropathy was described in detail. The role of the kidneys in glucose homeostasis, renal gluconeogenesis, and glucose reabsorption by the kidneys in healthy and in pathology is described. Detailed expositions of glycemic variability parameters, their changes in patients with diabetes mellitus depending on the stage of diabetic kidney damage are presented. The role of the kidneys in maintaining energy homeostasis, impaired glucose homeostasis in conditions of chronic kidney disease is described. We analyzed different options for insulin therapy, their advantages, and disadvantages in patients with diabetes mellitus with diabetic nephropathy. The presented material is extremely relevant for the development and implementation in the clinical practice of glycemic control methods to optimize treatment tactics, prevent the formation of microvascular complications, and early disability of patients with diabetes mellitus.
10 May 2023 in FOCUS. Endocrinology
Type 2 diabetes mellitus and obesity are two socially significant diseases, the prevalence of which has now assumed pandemic proportions. Obesity, as a rule, precedes the development of type 2 diabetes, being the most powerful risk factor for the development of this disease. In patients with obesity and type 2 diabetes with a BMI >35 kg/m2, bariatric surgery is recommended if glycemic control cannot be achieved after several attempts at non-surgical treatment of obesity. There is no doubt the effectiveness of bariatric surgery not only in the treatment of obesity, but also in achieving remission of type 2 diabetes. It seems relevant to study the predictors of achieving remission of type 2 diabetes, as well as factors that can worsen the prognosis. The purpose of the review: to study the effectiveness of metabolic surgery in achieving remission of type 2 DM, as well as predictors of remission of type 2 DM in obese patients after bariatric surgery.
1 January 2021 in Endocrinology: News, Opinions, Training
1 January 2021 in Endocrinology: News, Opinions, Training
AFAcademician I.P. Pavlov First St. Petersburg State Medical University of the Ministry of Healthcare of the Russian Federation
Academician I.P. Pavlov First St. Petersburg State Medical University of the Ministry of Healthcare of the Russian Federation
12 May 2021 in Bulletin of the Russian Military Medical Academy
The relationship between the level of glucagon-like peptide-1 and repeated weight gain was evaluated in 31 patients suffering from grade IIIII obesity and type 2 diabetes mellitus after bariatric interventions for 3 years. It was found that the level of stimulated glucagon-like peptide-1 significantly increased by the third day after sleeve gastroplasty and gastroschunt compared to the initial parameters (p = 0.001 for obese patients; p = 0.000 for obese patients and diabetes mellitus). In the plateau phase (body weight retention) after bariatric intervention, the level of stimulated glucagon-like peptide-1 in obese patients and patients suffering from obesity in combination with diabetes mellitus did not significantly differ from the indicators of healthy individuals. There was no association between the level of glucagon-like peptide-1 and repeated weight gain. This may be due to the limited contribution of glucagon-like peptide-1 to body weight dynamics after bariatric interventions and the predominance of patient compliance. Thus, the level of stimulated glucagon-like peptide-1 at baseline, on the third day and in the plateau phase after bariatric intervention was not associated with the value of repeated weight gain.